Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe

Abstract Crizotinib (XALKORI®) is indicated for anaplastic lymphoma kinase‐positive and ROS1‐positive advanced non‐small cell lung cancer. This study evaluated the distribution of the crizotinib patient information brochure (PIB) in Europe and patient knowledge of the key messages in the PIB. A cros...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kui Huang, Terri Madison, Beatrice Wehler, Marcello Tiseo, Keith D. Wilner, Jingping Mo
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2020-04-01
coleção:	Pharmacology Research & Perspectives
Assuntos:	crizotinib patient information brochure risk minimization survey
Acesso em linha:	https://doi.org/10.1002/prp2.570
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!